Filing Flows › Mangoceuticals (MGRX) › Q1 2026
Mangoceuticals (MGRX) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 19, 2026
Mangoceuticals (MGRX) reported revenue of $68K for the first quarter 2026 (Q1 2026), -38% from a year earlier and -28% from the quarter before.
Mangoceuticals, Q1 2026: revenue $68K (-38% year over year), net loss $3.4M, operating cash flow −$1.3M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $68K | -28% | -38% |
| Operating profit | −$3.1M | — | — |
| Net earnings | −$3.4M | — | — |
| Operating cash flow | −$1.3M | — | — |
What changed
Revenue was $68K in Q1 2026, down 38% year over year and down 28% from the previous quarter.
Gross margin was 42.7%, down 14.0 points from Q1 2025. Operating costs exceeded revenue by $3.1M, an operating margin of -4606.8%. Operating expenses fell 32% while revenue fell 38%. The quarter ended with a net loss of $3.4M, wider than the previous quarter's $2.8M loss.
Operating cash flow was −$1.3M. Non-cash charges added back $277K of depreciation and amortization and $1.1M of share-based compensation. Working capital and other items added $725K.
Questions
What was Mangoceuticals' revenue in the first quarter 2026?
Mangoceuticals (MGRX) reported revenue of $68K for the first quarter 2026 (Q1 2026), -38% from a year earlier and -28% from the quarter before.
Source: Mangoceuticals 10-Q on SEC EDGAR.